Amylon

Drug candidate targeting Katwijk disease

Amylon Therapeutics is developing a drug candidate that targets Katwijk disease, formally called hereditary cerebral haemorrhage with amyloidosis, Dutch type (HCHWA-D). Katwijk disease is a hereditary orphan disease first identified in the Dutch town of Katwijk.